Cancer biotech Syndax Pharmaceuticals files for a $69 million IPO

Comment

Shutterstock photo

Syndax Pharmaceuticals, a late-stage biotech developing an epigenetic therapy for treatment-resistant cancers, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. Its lead breast cancer candidate has been given Breakthrough Therapy designation by the FDA, and is currently in Phase 3 trials.

The Waltham, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol SNDX. Syndax Pharmaceuticals initially filed confidentially on November 15, 2013. Deutsche Bank and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com